There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Third Harmonic Bio, Inc. (THRD – Research Report) and Verve Therapeutics (VERV – Research Report) with bullish sentiments.
Third Harmonic Bio, Inc. (THRD)
In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on Third Harmonic Bio, Inc.. The company’s shares closed last Thursday at $6.36, close to its 52-week low of $3.75.
According to TipRanks.com, Slutsky is a 3-star analyst with an average return of
Currently, the analyst consensus on Third Harmonic Bio, Inc. is a Moderate Buy with an average price target of $5.00.
See Insiders’ Hot Stocks on TipRanks >>
Verve Therapeutics (VERV)
LifeSci Capital analyst Cory Jubinville, PhD maintained a Buy rating on Verve Therapeutics today and set a price target of $55.00. The company’s shares closed last Thursday at $17.94, close to its 52-week low of $13.01.
According to TipRanks.com, PhD is ranked #6468 out of 8549 analysts.
Verve Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $40.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on THRD:
- Third Harmonic Bio Announces Second Quarter 2023 Financial Results
- Target downgraded, Spotify upgraded: Wall Street’s top analyst calls
- Third Harmonic upgraded to Outperform from Market Perform at LifeSci Capital
- Third Harmonic Bio Announces Next-Generation Oral KIT Inhibitor Product Candidate THB335
- Third Harmonic Bio announces next-generation oral KIT inhibitor candidate
